Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for allegedly providing misleading information regarding its Phase 3 PALISADE-3 trial of fasedienol, leading to significant investor losses [2][7]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Vistagen common stock between April 1, 2024, and December 16, 2025, inclusive [2]. - Investors have until March 16, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that Vistagen made overwhelmingly positive statements while concealing material adverse facts about the Phase 3 PALISADE-3 trial [7]. - On December 17, 2025, Vistagen announced that the PALISADE-3 study did not show a statistically significant improvement on its primary endpoint, leading to a dramatic stock price decline from $4.36 to $0.86, a drop of over 80% [7]. Group 3: Next Steps for Investors - Investors who suffered losses or have information regarding the case are encouraged to contact Bragar Eagel & Squire for further assistance [4].

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: VTGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Vistagen and certain of ...

NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: VTGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Vistagen investors who were adversely affected by alleged securities fraud between April 1, 2024 and December 16, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/vistagen-thera ...

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose material adverse facts concerning its Phase 3 PALISADE-3 trial study of fasedienol, an ...

NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN). Shareholders who purchased shares of VTGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/vistagen-therapeutics-inc-loss-submission-form/?id=183258&from=3 CLASS ...

Core Viewpoint - Vistagen Therapeutics, Inc. is facing a securities fraud class action lawsuit, with a deadline for investors to act by March 16, 2026 [1][3][4]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of California on behalf of investors who purchased or acquired Vistagen common stock between April 1, 2024, and December 16, 2025 [4]. - The allegations include misrepresentations made by the Company and certain senior officers regarding the Phase 3 PALISADE-3 trial study of fasedienol, which is being developed for the treatment of social anxiety disorder [5]. Group 2: Investor Actions - Investors who wish to serve as lead plaintiffs must file necessary documents by March 16, 2026, but participation as a lead plaintiff is not required to share in any recovery [3]. - Shareholders are encouraged to contact the Investor Relations Manager for discussions regarding their legal rights and options [2][8]. Group 3: Law Firm Background - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has been recognized for its success in litigating class actions [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about its clinical trial results [2][5]. Group 1: Legal Investigation - The law firm is encouraging investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Vistagen, with a deadline of March 16, 2026, for investors to seek the role of lead plaintiff [2]. Group 2: Clinical Trial Results - Vistagen announced on December 17, 2025, that its Phase 3 PALISADE-3 trial for fasedienol, aimed at treating social anxiety disorder, failed to meet its primary efficacy endpoint, showing no statistically significant improvement compared to placebo [6]. - Following the announcement of the trial results, Vistagen's stock price dropped by $3.50, or 80.27%, closing at $0.86 on the same day [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December 16, 2025. Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. All representation is on a contingency fee basis. Shareholders pay no fees o ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Vistagen Therapeutics, Inc. common stock during the specified Class Period from April 1, 2024, to December 16, 2025, with a lead plaintiff deadline of March 16, 2026 [1] Group 1: Class Action Details - Investors who purchased Vistagen common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][7] - Investors wishing to serve as lead plaintiff must file a motion with the Court by March 16, 2026 [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class actions [4] Group 3: Case Background - The lawsuit alleges that Vistagen's defendants provided misleading information regarding the development and commercialization of its drug fasedienol, which is intended for the treatment of social anxiety disorder [5] - Defendants reportedly made positive assertions about fasedienol's trial success while concealing material adverse facts about the Phase 3 PALISADE-3 trial, leading to investor damages when the truth was revealed [6]

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for allegedly providing misleading information regarding its Phase 3 PALISADE-3 trial of fasedienol, leading to significant investor losses [2][8]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Vistagen common stock between April 1, 2024, and December 16, 2025, inclusive [2]. - Investors have until March 16, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that Vistagen made overwhelmingly positive statements while concealing material adverse facts about the Phase 3 PALISADE-3 trial [8]. - On December 17, 2025, Vistagen announced that the PALISADE-3 study did not show a statistically significant improvement on its primary endpoint, leading to a dramatic stock price decline [8]. Group 3: Financial Impact - Following the announcement of the trial results, Vistagen's stock price fell from $4.36 per share on December 16, 2025, to $0.86 per share on December 17, 2025, representing a decline of more than 80% [8].